GSK, Others Appeal UK Watchdog's Pay-For-Delay Penalties
GlaxoSmithKline has appealed the U.K. Competition and Market Authority's decision to fine it £37.6 million ($54.2 million) for paying to postpone generic versions of the antidepressant Seroxat, while other companies have...To view the full article, register now.
Already a subscriber? Click here to view full article